Eli Lilly and Company
↗Indianapolis, Indiana, USA
Eli Lilly and Company is a global pharmaceutical leader headquartered in Indianapolis, Indiana, founded in 1876. The company is now the most valuable pharmaceutical company worldwide and recently became the first healthcare stock to reach a market cap of $1 trillion. Eli Lilly focuses on innovative treatments across key therapeutic areas including cardiometabolic health (diabetes, obesity, cardiovascular), oncology, immunology, and neuroscience. The company has established dominant market positions in GLP-1 medications with blockbuster products Mounjaro and Zepbound, which generated $10.1 billion in combined revenue in Q3 2025 alone. In 2024, total company revenue reached $45.04 billion with earnings of $10.59 billion, representing 32% and 102% growth respectively compared to 2023.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Biopharmaceuticals, GLP-1 therapeutics, Oncology, Immunology
SIZE & FINANCIALS
Employees:10000+
Revenue:$45B
Founded:1876
Ownership:public
Status:operating
STOCK
Exchange:NYSE
Ticker:LLY
Market Cap:$933B-$1.02T
PIPELINE
Stage:Phase 1-Phase 3 and Commercial
Lead Drug Stage:Commercial - Mounjaro, Zepbound, Kisunla, Omvoh
Modalities:Small molecule, mAb (monoclonal antibodies), ADC (antibody-drug conjugates), GLP-1 receptor agonists, Gene therapy, AAV-based therapies
Active Trials:15
Trial Phases:Phase 1: 2 | Phase 2: 4 | Phase 3: 9
FDA Approvals:4
EMA Approvals:2
CORPORATE STRUCTURE
Subsidiaries:Elanco (formerly Eli Lilly Animal Health, spun off 2018)
Key Partnerships:Purdue University - $250M expansion through 2033 for pharmaceutical innovation, NVIDIA - collaboration to build largest pharma AI supercomputer, Alchemab Therapeutics - 5 antibody candidates for ALS, OliX Pharmaceuticals - MASH (liver disease) drug licensing, SanegeneBio - RNAi candidates for metabolic diseases, MeiraGTx - ophthalmology and gene therapy, Lila Biologics - solid tumor therapies, Indiana University - $40M to expand clinical trial access, University of Washington (David Baker lab) - protein-based therapeutics
COMPETITION
Position:Leader
Competitors:Novo Nordisk (Ozempic, Wegovy, Rybelsus), Pfizer (Dapagliflozin, oncology portfolio), Roche (oncology, diagnostics, Hemlibra), AstraZeneca (oncology, cardiovascular), Amgen (biologics, bone health), Johnson & Johnson (Janssen Pharma)
LEADERSHIP
Key Executives:
David A. Ricks - Chief Executive Officer, President and Chairman
Dr. Daniel M. Skovronsky - Executive Vice President, Chief Scientific Officer; President of Lilly Research Laboratories
Lucas Montarce - Chief Financial Officer and Executive Vice President
Diogo Rau - Executive Vice President and Chief Information and Digital Officer
Ilya Yuffa - Executive Vice President and President, Lilly USA and Global Customer Capabilities
Patrik Jonsson - Executive Vice President and President, Lilly Cardiometabolic Health
Scientific Founders:Eli Lilly (founder, 1876)
Board Members:David A. Ricks (Chairman and CEO), Jackson P. Tai, Marschall S. Runge, Vicki L. Sato, Michael J. Harrington, Jon Moeller (elected December 2024), Carolyn R. Bertozzi, Ph.D. (elected December 2025)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Eli Lilly and Company. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.